Singapore's NDR Medical (NDR), the leading interventional robotics company, extended its Asia-Pacific presence with the launch of its fourth office in Tokyo, Japan. The new office will be managed by Dr Kazumi Taguchi, NDR’s newly appointed Chief Medical Officer in Japan and Assistant Professor and head of research in Nephro-urology at Nagoya City University.

The new office will enable NDR to strengthen its partnerships with hospitals and collaborators in the Japanese market and adds to the company’s presence in the region alongside its headquarters in Singapore, as well as offices in Malaysia and China.

“The Automated Needle Targeting (ANT) solution developed by NDR has been proven to be safe and effective in various academic settings. I strongly believe it promises a brighter future and better healthcare outcomes for both physicians and patients,” said Dr Kazumi Taguchi, who is the principal investigator on NDR first clinical study conducted in Japan.

Bringing the benefits of Automated Needle Targeting (ANT)-X to more patients

NDR will launch its first multi-site trial in Japan for Automated Needle Targeting (ANT)-X with two university hospitals to evaluate the puncture superiority of ANT-X compared with conventional techniques. The trial is expected to commence in Q2 2022 and includes more than 100 patients. The trial will assist in obtaining Pharmaceuticals and Medical Devices Agency (PMDA) approval for later commercialization in Japan.

“Japan currently has the highest number of computed tomography (CT) machines per million population in the world. Getting early adoption in Japan helps to validate our technology, and affirms our approach for interventional procedures” said Alan Goh, CEO, NDR Medical.